Steven F. Bellon's most recent trade in Foghorn Therapeutics Inc was a trade of 140,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 22, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.50 per share. | 09 Sep 2024 | 20,000 | 101,957 | - | 9.5 | 190,000 | Common Stock |
Foghorn Therapeutics Inc | F. Bellon Steven | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 1,858 | 3,716 | - | - | Stock Options (Right to buy) | |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 11 Aug 2022 | 1,858 | 121,957 | - | 3.7 | 6,912 | Common Stock |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 3,717 | 5,574 | - | - | Stock Options (Right to buy) | |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.72 per share. | 25 May 2022 | 3,717 | 120,099 | - | 3.7 | 13,827 | Common Stock |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 675 | 0 | - | - | Stock Options (Right to buy) | |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.73 per share. | 25 May 2022 | 675 | 116,382 | - | 0.7 | 493 | Common Stock |
Foghorn Therapeutics Inc | Steven F. Bellon | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) |